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Summary
We conducted a large population-based survey of fragile
X (FRAXA) syndrome in ethnically diverse metropolitan
Atlanta. The eligible study population consisted of pub-
lic school children, aged 7–10 years, in special educa-
tion–needs (SEN) classes. The purpose of the study was
to estimate the prevalence among whites and, for the
first time, African Americans, among a non–clinically
referred population. At present, 5 males with FRAXA
syndrome (4 whites and 1 African American), among
1,979 tested males, and no females, among 872 tested
females, were identified. All males with FRAXA syn-
drome were mentally retarded and had been diagnosed
previously. The prevalence for FRAXA syndrome was
estimated to be 1/3,460 (confidence interval [CI] 1/
7,143–1/1,742) for the general white male population
and 1/4,048 (CI 1/16,260–1/1,244) for the general Af-
rican American male population. We also compared the
frequency of intermediate and premutation FRAXA al-
leles (41–199 repeats) and fragile XE syndrome alleles
(31–199 repeats) in the SEN population with that in a
control population, to determine if there was a possible
phenotype consequence of such high-repeat alleles, as
has been reported previously. No difference was ob-
served between our case and control populations, and
no difference was observed between populations when
the probands were grouped by a rough estimate of IQ
based on class placement. These results suggest that
there is no phenotype consequence of larger alleles that
would cause carriers to be placed in an SEN class.
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Introduction
Both fragile X (FRAXA) syndrome and fragile XE
(FRAXE) syndrome are caused by the expansion of a
trinucleotide repeat and are associated with a mental
retardation phenotype. Although these syndromes may
be linked by a common mechanism of expansion, they
are very different in terms of prevalence, phenotype, and
molecular basis of the syndrome.
FRAXA Syndrome
The prevalence of FRAXA syndrome is ∼1/4,000
males and 1/8,000 females (Turner et al. 1996). More
than 95% of cases of FRAXA syndrome are caused by
the hyperexpansion of a CGG trinucleotide repeat in the
5′ UTR of the gene FMR-1, located at Xq27.3 (Fu et al.
1991; Verkerk et al. 1991). As a consequence of the
hyperexpansion, the CpG island upstream of FMR-1 be-
comes hypermethylated, and no message is produced
(Pieretti et al. 1991; Sutcliffe et al. 1992; McConkie-
Rosell et al. 1993). The absent gene product of FMR-
1, called “FMRP,” normally is expressed as an RNA-
binding protein found to be highly expressed in the brain
and testis (Ashley et al. 1993).
In a normal population, the FRAXA CGG-repeat size
is highly polymorphic, within the range of 6–54 repeats,
and usually is inherited in a stable manner from parent
to offspring (Fu et al. 1991). The CGG repeat is not a
pure repeat and usually is interspersed with an AGG
every 9–10 CGGs (Kunst and Warren 1994). The CGG-
repeat sizes that are 60–200 repeats are termed “pre-
mutations,” because they tend to be inherited in an un-
stable manner and are a prelude to the full mutation.
Alleles of 41–60 repeats (intermediate alleles) sometimes
are considered to be in the “gray zone,” because they
overlap the normal and premutation repeat ranges and
may or may not be inherited unstably (Murray et al.
1996; Nolin et al. 1996; Zhong et al. 1996). Hyper-
expansions of 1200 repeats become hypermethylated
and are termed “full mutations.” Almost all males with
full mutations and 50% of females with full mutations
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exhibit FRAXA syndrome (Wolff et al. 1988; Rousseau
et al. 1994).
Males harboring the full mutation exhibit a wide
range of phenotypes, including a broad forehead, an
elongated face, large ears, and macro-orchidism. In
terms of behavior, males often have autistic-like features,
hyperactivity, tactile defensiveness, and a short attention
span (Hagerman 1996). The degree to which a male with
a full mutation is mentally impaired varies: mental re-
tardation ranges from profound to mild, with most being
moderately retarded (IQ 40–54) (Hagerman 1996).
Females with a full mutation often present with a
milder phenotype, compared with males, presumably be-
cause of X inactivation (Wolff et al. 1988; Rousseau et
al. 1994). Most often, affected females suffer from at-
tention deficits, impulsivity, and learning disabilities, al-
though a portion of affected females are overtly retarded
(Hagerman 1992). Those with severe problems tend to
have physical features similar to those of affected males
(Hagerman et al. 1991).
Unlike individuals with full mutations, carriers with
a premutation do not exhibit obvious clinical symptoms
of FRAXA syndrome, presumably because their FMR-
1 gene is not transcriptionally silenced. However, there
are data that suggest a phenotype consequence of the
premutation alleles. To date, the phenotype most con-
vincingly associated with premutation alleles is prema-
ture ovarian failure (POF), which is found to be signif-
icantly increased among female premutation carriers,
compared with the relatives of both noncarriers and full-
mutation carriers (Cronister et al. 1991; Schwartz et al.
1994; Conway et al. 1995; Partington et al. 1996; Con-
way et al. 1998; Murray et al. 1998; Allingham-Haw-
kins and International Collaborative POF in Fragile X
Study Group, in press).
Milder features of the cognitive, behavioral, and phe-
notypic traits associated with the full-mutation allele
have been reported to be associated with the premuta-
tion allele, although findings are inconclusive (Hull and
Hagerman 1993; Mazzocco et al. 1993; Reiss et al.
1993; Loesch et al. 1994; Allingham-Hawkins et al.
1996; Franke et al. 1996; Riddle et al. 1998). Little is
known about males with a premutation, but one study
suggests that these males have large ears and deficits in
nonverbal tasks, compared with non–fragile X carriers
(Loesch et al. 1994). However, there is no molecular
evidence for a phenotype associated with the premuta-
tion alleles, since it has been shown that FMR-1 gene
expression is comparable for normal and premutation
alleles (Feng et al. 1995).
FRAXE Syndrome
FRAXE syndrome is caused by the expansion of a
GCC repeat in the FMR-2 gene (Knight et al. 1993).
The prevalence of FRAXE syndrome is estimated to be
1/50,000 males, which is ∼14-fold less than the incidence
of FRAXA syndrome (Brown 1996; Knight et al. 1996).
The FRAXE locus, located at Xq27-28, is ∼600 kb distal
to FMR-1 (Sutherland and Baker 1992; Flynn et al.
1993). Like FMR-1, FMR-2 is associated with a nearby
CpG island that is hypermethylated on hyperexpansion
of the GCC repeat (Knight et al. 1993).
The FRAXE repeat is a pure repeat with no unique
interspersed sequences (Zhong et al. 1996). Normal
GCC alleles are 3–42 repeats. The border between the
normal allele and the premutation allele is still poorly
defined, because the FRAXE mutation is so rare.
Like those for FRAXA, full mutations for FRAXE
were believed to be 1200 repeats (Knight et al. 1993).
However, recent studies have shown that the hyperex-
pansion and subsequent methylation threshold may be
lower for the FRAXE locus (Hamel et al. 1994; Bian-
calana et al. 1996; Gecz et al. 1997). Furthermore, the
full-mutation phenotype for FRAXE syndrome has been
found to be much milder than the FRAXA phenotype.
Among the few families that have been described, pa-
tients tended to have behavioral problems and speech
delay (Dennis et al. 1992; Hamel et al. 1994; Mulley et
al. 1995; Knight et al. 1996; Barnicoat et al. 1997).
However, non–mentally impaired individuals who have
the FRAXE full mutation and the consequent lack of
FMR-2 expression also have been reported in the liter-
ature (Gecz et al. 1997). No studies to date have been
performed on FRAXE premutation carriers to assess the
possible impact of this allele.
FRAXA and FRAXE: Phenotype Association with
Normal Alleles
Like the premutation alleles, it is questionable whether
the FRAXA and FRAXE intermediate alleles are asso-
ciated with a phenotype. Murray et al. (1996) recently
reported an excess of intermediate/premutation FRAXA
(41–199 repeats) and FRAXE (31–199 repeats) alleles
in a population of English boys in special educa-
tion–needs (SEN) classes, when compared with maternal
control X chromosomes. This excess suggests that there
in fact may be a phenotype consequence of the inter-
mediate and premutation alleles, at either locus.
Evidence against a phenotype consequence of large,
unmethylated alleles is supported by at least two other
studies. Mazzocco et al. (1997) and Mornet et al. (1998)
both recently reported no excess of intermediate/pre-
mutation alleles in their respective populations. How-
ever, the former did not include controls, and the latter
used a small sample size.
To examine the phenotype consequence of the FRAXA
and FRAXE alleles, we surveyed a large, ethnically di-
verse population of school children in SEN classes in
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metropolitan Atlanta. The purpose of this study is sev-
eralfold: (1) to determine the frequency of the full-mu-
tation allele in both whites and African Americans in
SEN classes, as well as in the general population; (2) to
determine the phenotype of the full-mutation carrier in
this non–clinically referred population; and (3) to com-
pare the frequency of the premutation and intermediate
alleles in an SEN population with that in a control pop-
ulation, to determine if there is a possible phenotype
consequence related to cognitive ability and/or behavior.
We found that the prevalences of FRAXA syndrome,
premutation carriers, and the frequency of intermediate
alleles were similar to those reported previously. Fur-
thermore, we found that the prevalence of FRAXA syn-
drome among African American males appears to be
similar to that among white males, in metropolitan At-
lanta, which is ∼1/4,000. All identified males had the
classic phenotype of FRAXA syndrome. Last, we found
no evidence of an increased frequency of intermediate/
premutation alleles among FRAXA or FRAXE pro-
bands, when compared with a control population of
maternal untransmitted alleles.
Subjects and Methods
Study Population
The target population comprised public school chil-
dren, aged 7–10 years, in SEN classes in four of the five
districts of metropolitan Atlanta. The recruiting process
for the target population has been described elsewhere
(Meadows et al. 1996). A buccal brush or mouth-wash
sample was obtained from each participating child, and
a separate invitation packet requesting buccal brush
samples was sent to the mother and father of each child.
Laboratory Methods
FRAXA and FRAXE allele sizes were determined by
a fluorescent method described elsewhere (Meadows et
al. 1996). Male samples that failed to amplify and female
samples that revealed a single band for FRAXA, by
means of this method, were subjected to a second PCR
protocol, described elsewhere (Brown et al. 1993). We
were unable to pursue those samples that did not yield
results when the method described for FRAXE was used.
If the second PCR procedure did not yield conclusive
results for the sample in question, the individual was
approached for a blood sample, to examine the FRAXA
locus by use of a Southern blot protocol (Meadows et
al. 1996).
If an individual with inconclusive results was unable
to submit a blood sample, the DNA from the buccal or
mouth-wash sample was used to test for the expanded
FRAXA alleles, by use of Expand Long Template Poly-
merase (Boehringer Mannheim). The DNA for each sam-
ple was diluted to 1 ng/ml, and 1 ml of the diluted sample
was used for each PCR reaction. Amplification of ge-
nomic DNA was performed with 0.7 mM each of prim-
ers C and F, in a 15-ml cocktail mix of 1# assay buffer
containing 1.75 mM MgCl2 (Boehringer Mannheim);
10% dimethyl sulfoxide; 500 mM dATP, dCTP, dTTP,
and 7-deaza dGTP; 0.25 mM MgCl2; and 1 U Expand
Long Template Polymerase (Boehringer Mannheim).
The reactions were heated to 95C for 10 min, followed
by five cycles of denaturation at 95C for 2.5 min, an-
nealing at 65C for 1 min, and elongation at 72C for
2.5 min. The samples were further subjected to 25 cycles
of denaturation at 95C for 1.5 min, annealing at 55C
for 1 min, and elongation at 72C for 2.5 min, followed
by a final elongation step at 72C for 5 min. Five mi-
croliters of loading dye was added to the PCR reaction
and was denatured at 95C for 5 min before being loaded
onto a 6% acrylamide gel (Gibco-BRL). The gel
( cm) was run for ∼1 h 15 min. The DNA was17 # 17
transferred to a positively charged membrane (Boehrin-
ger Mannheim) and was prehybridized and hybridized
in accordance with the manufacturer’s instructions. The
probe (CGC)7 was 3
′ end labeled in accordance with the
manufacturer’s instructions. After the application of
CDP-STAR (Boehringer Mannheim), the DNA was vi-
sualized by use of autoradiography, typically after a
3–15-min exposure. For each gel, a set of controls,
including a blank control (double-deionized water), and
samples from normal, premutation, and full-mutation
individuals of each sex were run. Consistent with our
results, it has been shown previously that the Expand
Long PCR procedure can be used to amplify premuta-
tion and full-mutation alleles (Hecimovic et al. 1997).
Statistical Methods
A x2 test of independence or a Fisher’s exact test using
the software StatXact (Cytel) was performed to compare
genotypes or allele distributions. The difference between
the observed and expected heterozygosities was tested
as described elsewhere (Meadows et al. 1996).
Power calculations were performed by use of the fol-
lowing equation:
1/2 1/2Z  2[Farcsine(p )  arcsine(p ) F](.05) 1 2
1/2# [(N N )/(N N )]  1.96 ,1 2 1 2
where p1 and p2 are the frequencies of intermediate/pre-
mutation alleles in case and control populations, re-
spectively, N1 is the sample size of the case population,
and N2 is the sample size of the control population (Mo-
tulsky 1995). For purposes of comparison between the
present study and that of Murray et al. (1996), we set
and for the FRAXA locus andp  .0355 p  .0191 2
and for the FRAXE locus. In cal-p  .011 p  .00281 2
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Table 1
Sample Size and Participation Rates, by District
DISTRICT
SAMPLE SIZE (PARTICIPATION RATE)
Probands Mothers Fathers
1 902 (.39) 360 (.40) 281 (.31)
2 551 (.51) 184 (.34) 126 (.23)
3 469 (.43) 127 (.26) 80 (.17)
4 1,034 (.52) 369 (.36) 296 (.29)
Total 2,956 (.46) 1,040 (.35) 783 (.27)
NOTE.—The participation rates of the parents include only those
parents whose child provided a sample.
culating the 95% confidence intervals (CIs), we used the
equations recommended by Fleiss (1981), because the
frequencies of the full-mutation, premutation, and in-
termediate alleles were near 0.
Results
Study Population
Eligible subjects were children, aged 7–10 years, who
attended SEN classes (i.e., had an active individual ed-
ucational program) in the public school system of At-
lanta. We excluded children in resource speech, as well
as those in gifted classes. Both males and females and
all ethnic groups were included in this study. Subjects
were not excluded on the basis of known etiology. The
participation rate was 46% (table 1). The study popu-
lation was comparable to the target population, with
regard to sex, ethnicity, and primary educational need
(table 2 and data not shown). The participation rate of
mothers and fathers in our study was 35% and 27%,
respectively (table 1). We obtained samples from 2,873
of the 2,956 children who had parental consent. The
remaining 83 cases moved out of the school system be-
fore a sample was obtained and could not be tracked,
owing to lack of a forwarding address. Of the DNA
samples received, 22 (0.77%) failed to give FRAXA re-
sults, and 221 (7.69%) failed to give FRAXE results.
Unlike for the FRAXA locus, we did not attempt to
identify further the carrier status of females who had a
single band or individuals who repeatedly failed to am-
plify for the FRAXE locus. Thus, we were unable to
identify any FRAXE full-mutation individuals and pos-
sibly some FRAXE premutations in samples that did not
amplify by use of the primary PCR method (see Subjects
and Methods). Since we were able to follow up all
FRAXA failed samples, using a more sensitive assay, we
found that the failure to amplify at the FRAXA locus
probably was not due to an expanded allele in these
samples. Rather, the DNA most likely was of poor qual-
ity, since we could not amplify the surrounding markers
in these samples. In testing for the FRAXA and FRAXE
loci, we identified several sex-chromosome abnormali-
ties in our SEN population (table 3). We identified one
47,XXX female (0.03%) and seven 47,XXY males
(0.24%). We also had two Turner syndrome females
(0.07%) who had been diagnosed previously, as indi-
cated on their consent forms. These findings are in agree-
ment with those of other studies (Dawson et al. 1995;
Holden et al. 1995).
FRAXA: Prevalence
We identified five FRAXA full-mutation males and no
females. One of the five full-mutation males was African
American, and the others were white. All these full-mu-
tation individuals had been diagnosed previously; thus,
we did not identify any new cases of FRAXA syndrome
in this survey. All had a typical fragile X phenotype for
males, and all were in SEN classes, because of mental
retardation. For white and African American males in
an SEN population, we calculated the prevalence of
FRAXA syndrome to be 1/362 (CI 1/1,129–1/132) and
1/422 (CI 1/8,066–1/66), respectively (table 4). Al-
though the confidence limits are wide, there was no dif-
ference in rates between white and African American
males. To calculate the prevalence in the general pop-
ulation, we assumed that all individuals with FRAXA
syndrome would be found in SEN classes; that is, we
did not expect individuals with FRAXA syndrome to be
attending non-SEN classes. Furthermore, we assumed
that the rate of individuals with the syndrome was the
same in the participating SEN population as in the non-
participating SEN population. On the basis of these as-
sumptions, we estimated the overall prevalence among
males to be 1/3,968 (CI 1/7,353–1/2,188).
We identified only two FRAXA premutations, and
both were in white females. Thus, the prevalence of
FRAXA premutation carriers among white females was
estimated to be 1/317 (CI 1/832–1/79). Although we did
not identify any new cases of FRAXA syndrome among
probands, we did identify a new case of FRAXA syn-
drome through one of the newly identified female
FRAXA premutation carriers. We did not identify any
male FRAXA premutation carriers among whites or Af-
rican Americans in our SEN population (table 4).
Because the intermediate alleles (41–60 repeats) are
thought to be precursors of premutation alleles, we ex-
amined the prevalence of carriers among both whites
and African Americans (table 4). Although not statis-
tically different, the prevalence among male and female
carriers was lower for African Americans, compared
with whites. Furthermore, among African Americans the
ratio of female to male carriers of intermediate alleles
was 0.72:1, whereas among whites the ratio (1.46:1;
table 4) was closer to the 2:1 ratio expected for an X-
linked neutral allele.
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Table 2
Description of Study Population: Frequencies for Sex, Ethnicity, and Primary Educational Need, by
District
DISTRICT
FREQUENCY
Sex Ethnic Group Primary Educational Need
M F W AA O
Emotional
Behavioral
Disorder
Learning
Disabled
Mentally
Retarded
Other
Health
Impaired Othera
1 .68 .32 .80 .16 .04 .18 .53 .11 .14 .04
2 .67 .33 .58 .36 .07 .15 .60 .14 .05 .06
3 .69 .31 .57 .38 .05 .21 .43 .29 .00 .07
4 .72 .28 .82 .10 .07 .25 .43 .13 .12 .07
Total .70 .30 .73 .21 .06 .20 .49 .15 .09 .06
NOTE.—M  male, F  female, W  white, AA  African American, and O  Other.
a Autistic, orthopedically impaired, deaf and/or blind, visually or hearing impaired, traumatic brain
injury, or self-contained speech.
FRAXE: Prevalence
As discussed in Subjects and Methods, we were not
able to detect FRAXE full-mutation carriers by using
our assay. We identified only one male premutation car-
rier of 63 repeats, who was African American, and no
female carriers. Because we did not follow up the
FRAXE PCR failures, this number may represent an un-
derestimation (table 5). We also examined the frequency
of the intermediate alleles (31–60 repeats) and found
that the ratio of female to male carriers was 1:1.29 for
whites and 1.5:1 for African Americans (table 5). These
carrier ratios should be interpreted with caution, because
the number of FRAXE intermediate alleles was quite
small for both ethnic groups (whites, ; Africann  16
Americans, ).n  5
FRAXA: Allele Distribution and Heterozygosity
All probands were used to generate allele distributions
for the FRAXA locus ( alleles). The overalln  3,724
distribution for the FRAXA locus was similar to that
reported elsewhere (Meadows et al. 1996). The allele
distribution for whites was then compared with that for
African Americans. Overall, the FRAXA distribution for
whites ranged from 11 to 1200 repeats and had 52 dis-
tinct alleles, whereas the distribution for African Amer-
icans had an identical range but only 34 distinct alleles
(table 6). Interestingly, the difference in the number of
distinct alleles between the two ethnic groups was driven
by the diversity of the intermediate alleles in whites: there
were 20 distinct intermediate alleles in whites and 6 dis-
tinct intermediate alleles in African Americans. To better
understand the difference between the two distributions
and to test for significance, the allele sizes were collapsed
into three categories (11–26 repeats, 27–34 repeats, and
134 repeats) based on the antimode of the overall dis-
tribution for the FRAXA locus. A significant difference
between whites and African Americans was observed for
the FRAXA alleles ( , ), and this dif-2x  61.7 P ! .0012
ference was primarily due to two observations: there was
a lower frequency of smaller alleles, such as alleles of
20 and 23 repeats, and a lower frequency of alleles 140
repeats in the African American population, compared
with whites. In fact, with respect to the allele frequency
of the intermediate alleles (41–60 repeats), only 2.2%
of the African American alleles fell within this category,
whereas 4.0% of the white alleles fell within the same
category, as is reflected by the carrier frequencies for
these alleles, shown in table 4.
Hardy-Weinberg equilibrium for the FRAXA locus
was then examined in each population. To do this, the
level of heterozygosity for each population was exam-
ined and compared with that predicted from the allele
distribution for males (see Statistical Methods). At the
FRAXA locus, African Americans showed reduced levels
of heterozygosity, whereas whites fit the expected level
(table 6).
FRAXE: Allele Distribution and Heterozygosity
As we did for FRAXA, we collapsed the FRAXE dis-
tribution ( alleles) into three categories (3–11n  3,431
repeats, 12–20 repeats, and 120 repeats) based on the
antimode of the overall distribution, to test for a sig-
nificant difference between the two populations. A dif-
ference between whites and African Americans was ob-
served at the FRAXE locus ( , ), and2x  24.7 P ! .0012
this difference was primarily due to the higher frequency
of smaller alleles in the African American population,
compared with whites. Overall, the FRAXE distribution
for whites was 7–54 repeats and had 34 distinct alleles,
whereas the distribution for African Americans had a
similar range and only 27 distinct alleles (table 6). The
diversity of alleles in the distribution for whites, com-
pared with that in the distribution for African Ameri-
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Table 3
Study Populations by Sex and Ethnicity, for FRAXA
POPULATION
NO. OF MALES NO. OF FEMALES
Total W AA O Total W AA O
Generala 46,523 30,653 11,667 4,203 44,444 29,055 11,432 3,957
Targetb 4,648 3,207 1,214 227 1,816 1,260 465 91
Study:
Full mutation 5 4 1 0 0 0 0 0
Premutation 0 0 0 0 2 2 0 0
Intermediate 78 64 13 1 48 41 4 3
Common 1,889 1,373 407 109 819 590 175 54
XXY 7 6 1 0 0 0 0 0
XXX 0 0 0 0 1 1 0 0
XO 0 0 0 0 2 1 1 0
Total 1,979 1,447 422 110 872 635 180 57
NOTE.—W  white, AA  African American, and O  Other.
a Children, aged 7–10 years, in the public school system during the time of the survey of each
district.
b Children, aged 7–10 years, in SEN classes.
cans, was driven, like at the FRAXA locus, by the di-
versity of the intermediate alleles within that population.
The observed heterozygosity at the FRAXE locus was
compared with that predicted by the allele distribution
for males. Unlike for the FRAXA locus, reduced levels
of heterozygosity were observed in both populations (ta-
ble 6).
Testing for Phenotype Consequence of Normal FRAXA
and FRAXE Alleles
Murray et al. (1996) recently demonstrated that there
was an excess of intermediate/premutation FRAXA
(41–199 repeats) and FRAXE (31–199 repeats) alleles
in their SEN population of boys from Wessex, England.
In view of these results, it was suggested that there
could be a phenotype associated with these large, un-
methylated alleles. To test this possibility in our SEN
population, the frequency of intermediate/premutation
FRAXA and FRAXE alleles among the probands was
compared with that among controls, by use of a
“matched” and “unmatched” approach. For the
matched approach, the transmission of alleles from
mother to proband was examined. The allele transmitted
to the proband was considered the “case” allele, and the
allele not transmitted to the proband was considered the
“control” allele. For probands identified in this study as
siblings, each transmission was considered an indepen-
dent event. For this analysis, the population was not
separated by ethnicity, because the control alleles served
as ethnic matches to the case alleles. The case and control
alleles were categorized according to repeat sizes similar
to those used by Murray et al. (1996). In this SEN pop-
ulation, intermediate/premutation alleles were slightly
more frequent in the case population for the FRAXA
locus; however, this difference did not reach statistical
significance ( ; table 7). There was no differ-P  .6981
ence between the case and control populations for the
FRAXE locus ( ; table 7). For the unmatchedP  1.000
approach, all proband alleles, not just those from ma-
ternal samples, were considered the case alleles. The pop-
ulation of maternal untransmitted alleles, as well as of
paternal untransmitted alleles, was used as the control
population. For this analysis, both cases and controls
were separated by ethnicity. We found no difference be-
tween the unmatched case and control populations, for
either whites or African Americans, at the FRAXA locus
( and , respectively; table 7) or atP  .8447 P  .7600
the FRAXE locus ( and , respec-P  1.000 P  .6161
tively; table 7).
Because these data contradict those of Murray et al.
(1996), we further investigated our population to un-
cover any possible heterogeneity by school district or by
IQ level. First, we analyzed our matched case and control
populations by district. There was no significant statis-
tical evidence of heterogeneity ( ; table 8); how-P  .06
ever, the frequencies did fluctuate from district to district.
Second, we analyzed our matched case and control
populations according to a rough estimate of IQ. Our
study encompassed many learning-impaired phenotypes,
among which mental retardation accounted for only
15% of the study population (table 3). Intermediate/
premutation alleles may be associated with a more severe
phenotype, such as IQ !70. Because we did not have
access to school records, we based IQ on class place-
ment. For some individuals we were unable to ascertain
class placement. Those who were placed in classes be-
cause of mental retardation, severe behavioral disorders,
and autism were classified as IQ !70, and the remainder
were classified as IQ 70. The frequency of interme-
diate/premutation alleles was essentially the same for
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Table 4
Prevalence of FRAXA Full-Mutation, Premutation, and Intermediate Alleles
POPULATIONa
PREVALENCE (95% CI) AMONG MALES PREVALENCE (95% CI) AMONG FEMALES
Total W AA Total W AA
Full mutation:
Target 1/396 1/362 1/422 0/872c 0/635c 0/180c
(1/1,074–1/160) (1/1,129–1/132) (1/8,066–1/66)
General 1/3,968 1/3,460 1/4,048 ) ) )
(1/9,353–1/2,188) (1/7,143–1/1,742) (1/16,260–1/1,244)
Premutation:b
Target/general 0/1,979 0/1,447 0/422 1/436 1/317 0/180
(1/2,519–1/109) (1/1,832–1/79)
Intermediate:b
Target/general 1/25 1/23 1/32 1/18 1/15 1/45
(1/32–1/20) (1/29–1/18) (1/58–1/19) (1/24–1/14) (1/21–1/11) (1/140–1/17)
NOTE.—W  white, AA  African American, and O  Other.
a Target  children, aged 7–10 years, in SEN classes. General  children, aged 7–10 years, in the public school system during the time of
the survey of each district.
b Prevalence in the general population was assumed to be that found in the target population, since no differences between cases and controls
were found (see text).
c No individuals were observed; thus, prevalences could not be estimated.
both groups. We also examined this possible association
by district, since each district has different criteria for
placement. Again, we found no evidence of heteroge-
neity, although estimates did fluctuate (data not shown).
Discussion
Prevalence
The prevalence 1/3,460 (CI 1/7,143–1/1,742) esti-
mated here for FRAXA syndrome in a white male pop-
ulation is in agreement with that determined in previous
studies (Murray et al. 1996; Turner et al. 1996; de Vries
et al. 1997; Morton et al. 1997; Syrrou et al. 1998). On
the basis of this estimate, we project the prevalence
among females to be ∼1/9,000, assuming that ∼50% of
female full-mutation carriers exhibit the syndrome
(Rousseau et al. 1994) and that the frequency of male
and female full-mutation carriers is equal (Sherman
1995a). Consistent with this expectation and our limited
sample size, we did not identify any females with a full-
mutation allele. Interestingly, no new FRAXA syndrome
cases were discovered among the probands, although
one undiagnosed male was ascertained through a female
proband with a premutation and was identified by use
of the Expand Long PCR procedure. Because we were
specifically targeting children, aged 7–10 years, in SEN
classes, the lack of new cases indicates that the vast ma-
jority of cases are being diagnosed before age 7 years.
As mentioned previously, to calculate the prevalence
of FRAXA syndrome in the general population, we as-
sumed that the numbers of FRAXA syndrome cases in
our participating and nonparticipating populations were
equal. Using the school record–surveillance system of
developmental disabilities established by the Centers for
Disease Control and Prevention (CDC), we were able to
identify the number of males and females with FRAXA
syndrome who met the proper criteria at the time of
ascertainment but who did not participate in our study.
Two males (districts 1 and 4), one female (district 1)
with FRAXA syndrome, and one female (district 1) with
possible FRAXA syndrome did not participate in our
survey. Thus, our assumption seemed to be confirmed.
However, there is still a possibility that mothers who
express the FRAXA syndrome were less willing both to
participate and to pursue a diagnosis for their child; thus,
these cases would be missed by both our screening study
and the CDC surveillance. If true, our prevalence esti-
mate is an underestimate of the true rate.
Anecdotally, there is a lack of African Americans with
FRAXA syndrome reported in the literature (Howard-
Peebles and Stoddard 1980; Venter et al. 1981; Venter
and Op’t Hof 1982). This could be due to either a true
lower prevalence, resulting from the mutation history of
the population, or an underascertainment of cases. We
identified one African American male with a FRAXA
full mutation who had been diagnosed previously. The
resulting prevalence for this population was similar to
that for whites, that is, 1/4,048 (CI 1/16,260–1/1,244).
To our knowledge, this is the only reported estimate
for African Americans that is based on a large, non–
clinically referred population survey using a molecular
diagnosis for FRAXA syndrome. A recent study in South
Africa gave similar results: the prevalence of FRAXA
syndrome among institutionalized South African blacks
was similar to that reported in the literature for insti-
tutionalized white populations (Goldman et al. 1997).
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Table 5
Study Populations by Sex and Ethnicity, for FRAXE
POPULATION
NO. OF MALES NO. OF FEMALES
Total W AA O Total W AA O
Generala 46,523 30,653 11,667 4,203 44,444 29,055 11,432 3,957
Targetb 4,648 3,207 1,214 227 1,816 1,260 465 91
Study:
Full mutation 0 0 0 0 0 0 0 0
Premutation 1 0 1 0 0 0 0 0
Intermediate 11 9 2 0 11 7 3 1
Common 1,847 1,350 395 102 773 565 161 47
XXY 7 6 1 0 0 0 0 0
XXX 0 0 0 0 0 0 0 0
XO 0 0 0 0 2 1 1 0
Total 1,866 1,365 399 102 786 573 165 48
NOTE.—W  white, AA  African American, and O  Other.
a Children, aged 7–10 years, in the public school system during the time of the survey of each
district.
b Children, aged 7–10 years, in SEN classes.
Furthermore, Pulliam et al. (1988) showed that the per-
centage of institutionalized African American males with
FRAXA syndrome who were diagnosed cytogenetically
agreed with the percentage of African American males
in the general population of South Carolina. Finally, a
recent study by Elbaz et al. (1998) showed that the prev-
alence of FRAXA syndrome among a mostly Afro-Ca-
ribbean male population was similar to that among
whites. These findings, as well as the prevalence reported
here, suggest that the prevalence of FRAXA syndrome
among white and African American populations does
not differ.
With respect to premutation carriers, Rousseau et al.
(1995) screened 10,624 unselected French Canadian
women and estimated the prevalence of premutation car-
riers (55–199 repeats) to be 1/259 women (95% CI
1/373–1/198). If only those with61 repeats are defined
as premutation carriers, the estimate is 1/379. When
these results were reported, two explanations were of-
fered to explain the high prevalence of carriers in the
Quebec population: (1) a founder effect in the French
Canadian population and (2) a true high prevalence of
carriers of the FRAXA premutation allele (Sherman
1995b). On the basis of our prevalence estimate of
1/317 (CI 1/1,832–1/79) in this survey of an admixed,
presumably northern European white population, the
latter explanation is the more likely of the two
possibilities.
We did not identify any male FRAXA premutation
carriers in our proband population. However, we did
identify two male premutation carriers among our con-
trol population of 433 fathers ascertained through sons.
Because our analyses showed that the allele distribution
in our proband population did not differ from that in
our control population, we combined these populations,
for a prevalence of white male premutation carriers of
1/923 (CI 1/5,319–1/229). Murray et al. (1996) also
reported 1 male premutation carrier among 1,013 males
in Wessex, England. We did not identify any FRAXA
premutation carriers among our African American
population.
The higher frequency of premutation alleles among
females, versus males, in this population, as well as
among the French Canadian population (Rousseau et al.
1995), was predicted from models that assume that ex-
pansion of the CGG repeat occurs meiotically, not post-
zygotically; that is, for models that assume prezygotic
expansion and subsequent selection against sperm with
full mutations, the ratio of female to male premutation
carriers is predicted to be ∼2.6 (Winter 1987; Sved and
Laird 1990; Morton and Macpherson 1992; Kolehmai-
nen 1994; Morris et al. 1995a, 1995b). In contrast, the
model that assumes postzygotic expansion restricted to
maternal X chromosomes predicts the female to male
ratio to be ∼1.2 (Ashley and Sherman 1995). The prev-
alence estimates from our survey reflect a 2.9 ratio,
which provides indirect evidence for the prezygotic ex-
pansion model.
Because the intermediate alleles may represent the al-
leles predisposed to expand to the premutation state, we
calculated the prevalence of these alleles in both popu-
lations. Interestingly, the African American population
had a lower prevalence of these alleles (2.2%), compared
with whites (4.0%). It has been proposed that, for other
trinucleotide-repeat diseases, such as myotonic dystro-
phy (DM), the smaller frequency of intermediate alleles
leads to a lower prevalence of the disease in that par-
ticular ethnic population (Ashizawa and Epstein 1991;
Goldman et al. 1994; Watkins et al. 1995). Although
our African American population had a lower preva-
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Table 6
Description of FRAXA and FRAXE Distributions among Whites and African
Americans
NO. OF ALLELES HETEROZYGOSITY
Mean Range Total Expected Observed
FRAXA:
Whites 29.57 11–200 52 .813  .010 .823  .011
African Americans 30.11 11–200 34 .812  .019 .760  .023a
FRAXE:
Whites 17.59 7–54 34 .858  .009 .786  .012a
African Americans 16.75 7–63 27 .842  .018 .767  .023a
a (two-sided z-test).P ! .05
Table 7
Frequency of Intermediate/Premutation Alleles among Cases and Controls, in a Matched and
Unmatched Design
STUDY DESIGN
AND ALLELE TYPE
ALLELE FREQUENCY
FRAXA, 41 Repeats FRAXE, 31 Repeats
Matched:
Transmitted 33/844 (.04) 4/657 (.01)
Untransmitted 29/844 (.03) 4/657 (.01)
Whites African Americans Whites African Americans
Unmatched:
Proband 110/2,718 (.04) 17/782 (.02) 18/2,502 (.01) 6/725 (.01)
Controla 37/891 (.04) 2/127 (.02) 6/887 (.01) 0/102
a Maternal untransmitted alleles and paternal untransmitted alleles, ethnically matched.
lence of intermediate alleles, compared with whites, this
population did not have a lower prevalence of disease
alleles. This contrast to other repeat diseases needs to
be confirmed, since the confidence limit was large in our
estimate of the prevalence of FRAXA syndrome in the
African American population. Although there are fewer
intermediate alleles in the African American population,
the proportion of alleles that contain a CGG/AGG-re-
peat structure susceptible to expansion may be equal,
compared with that in the white population. Sequence
data on African American intermediate alleles are nec-
essary to confirm or deny this hypothesis.
Possible Phenotype Consequence of Normal Alleles
We found no evidence for an excess of intermediate/
premutation alleles at the FRAXA and FRAXE loci in
an SEN population, in contrast to the findings of Murray
et al. (1996), the only other large study of an SEN pop-
ulation with controls. It is important to try to understand
the differences between the two studies, since one ex-
planation is a phenotype consequence of high-repeat al-
leles. If true, the result would have important implica-
tions in terms of both the impact on cognition and/or
behavior (Teague et al. 1998) and the biological role of
the CGG-repeat region in these genes. Our investigation
was comparable both in the definition of cases (individ-
uals in SEN classes) and controls (maternal X chro-
mosomes) and in the definition of intermediate/premu-
tation alleles (140 repeats for FRAXA and 130 repeats
for FRAXE). However, the target populations clearly
differed. In our study, both boys and girls, aged 7–10
years, were included, whereas Murray et al. included
boys aged 5–18 years. Also, the proportion of individ-
uals with mental retardation was higher in the study
by Murray et al. (∼33%; P. A. Jacobs, personal com-
munication), compared with that in our population
(∼15%), although both estimates were crude. The pro-
portions of individuals and the criteria of other types of
educational needs also probably differed between the
Atlanta and Wessex populations. Last, our population
consisted of many ethnic groups, the two most promi-
nent being whites and African Americans, whereas the
population studied by Murray et al. consisted almost
exclusively of whites.
If there is a phenotype consequence of intermediate/
premutation alleles, any or all of these differences be-
tween populations could result in differences in the
power to identify an effect. For example, the increased
age structure of the population studied by Murray et al.
(1996) could increase the power to detect a gene that
plays a role in the cognitive ability and/or behavioral
profile of an individual. Behavioral genetic studies of
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Table 8
Test of Homogeneity: Frequency of Intermediate/Premutation
Alleles among Cases and Controls, by District and by IQ
PARAMETER
ALLELE FREQUENCY
FRAXA, 41 Repeats FRAXE, 31 Repeats
Cases Controls Cases Controls
District:
1 17/303 (.06) 6/303 (.02) 3/256 (.01) 1/256 (.01)
2 4/164 (.02) 9/164 (.06) 0/136 1/136 (.01)
3 3/97 (.03) 4/97 (.04) 1/65 (.01) 0/65
4 9/280 (.03) 10/280 (.04) 0/199 2/199 (.01)
IQ:
70 29/652 (.04) 22/652 (.03) 3/517 (.01) 3/517 (.01)
!70 3/102 (.03) 3/102 (.03) 1/68 (.01) 1/68 (.01)
many traits show that heritability estimates are higher
for adults, compared with those for children (McCartney
et al. 1990). With respect to the proportion of individ-
uals with mental retardation, neither our study (table 8)
nor that of Murray et al. (P. A. Jacobs, personal com-
munication) showed an association with the crude cat-
egorization of mental retardation. However, neither
study had the ability to examine an association with
severity or types of behavioral problems. Last, the fre-
quency of genes that may modify the action of the
FRAXA allele or that may be modified by the increased
repeat number might differ between studies, because of
the ethnic variation.
Another explanation for the difference in the ability
to detect an excess of intermediate/premutation alleles
simply could be related to the sample size. We examined
the frequency of the tail of the distribution, a frequency
that is !5% of the population; thus, large numbers are
needed to detect significant differences. In this respect,
the African American component of our study popula-
tion could have had a major impact on the detection of
an excess of intermediate/premutation alleles, since this
population, in general, has been shown to have a lower
frequency of these particular alleles. Our data did show
the same trend of an excess of intermediate/premutation
alleles at the FRAXA locus, but these data failed to reach
significance. Because we failed to reject the null hypoth-
esis, we calculated the power of this study to detect the
difference observed by Murray et al. (1996) (see Statis-
tical Methods). For the unmatched case/control FRAXA
analysis of whites, the present study had a 75% prob-
ability to detect a difference of 1.65% between case and
control populations, when the control frequency was
assumed to be 1.9%. For FRAXE, the present study had
a 72% probability to detect a difference of 0.82%, when
the control frequency was assumed to be 0.28%.
The alternative possibility is that there is no phenotype
consequence of intermediate/premutation alleles and
that the results of Murray et al. (1996) simply are due
to statistical fluctuation. Evidence that supports the idea
of statistical fluctuation is the fact that the frequencies
of intermediate/premutation alleles among control ma-
ternal X chromosomes in the present study and in the
study by Murray et al. are different. We found that 3%
of control alleles are in the intermediate/premutation
range, which is similar to that estimated in other studies
of general populations (Dawson et al. 1995; Holden et
al. 1995; Spence et al. 1996; Mornet et al. 1998; Haddad
et al., in press). However, in the study by Murray et al.,
the frequency of intermediate alleles was only 1.9%.
This difference was unexpected, given the similar defi-
nition of controls.
A priori, one would not expect a phenotype to be
associated with FRAXA intermediate alleles. There is
inconsistent evidence for a cognitive and/or behavioral
phenotype related to premutation males and females (see
Introduction). This is not surprising, given that pre-
mutation alleles are not hypermethylated and seem to
produce amounts of FMRP similar to those produced
by normal alleles (Feng et al. 1995). If a phenotype is
not observed among premutation carriers, then one may
not be expected among individuals with intermediate
alleles. However, there is a strong correlation between
premature menopause and female premutation carriers
only (see Introduction). This association argues for the
deleterious function of a large CGG repeat. Recent ev-
idence regarding another trinucleotide-repeat disease,
DM, suggests a mechanism for a gain of function re-
sulting from an increased number of repeats. Philips et
al. (1998) found that the normal activity of a CUG-
binding protein was disrupted as the number of repeats
in the RNA of the DMPK gene increased. This resulted
in the abnormal splicing of a certain family of genes.
Since there are known CGG-specific DNA-binding pro-
teins (Deissler et al. 1996), this type of mechanism could
induce altered expression related to increased repeat
numbers at the FRAXA locus.
On the basis of our study, the FRAXA and FRAXE
intermediate/premutation alleles do not seem to have an
impact on IQ. Clearly, more studies using proper case
and control populations, with large sample sizes, are
needed, to resolve this contradictory observation.
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